Roadmap
2013
The world’s first Institute for Exposomic Research established at Mount Sinai in 2013 with Manish Arora, PhD as the co-founder and director of environmental exposure and precision environmental medicine laboratories, leading a team of over 50 scientists advancing research in a vast array of diseases that are national health priorities, including autism, ALS, cancers, and gastrointestinal disorders
2016
Dr. Manish Arora awarded the U.S. Presidential Early Career Award for Scientists and Engineers (PECASE)
2019
NIH grants of $25 million awarded to Dr. Arora and researchers at the Mt. Sinai Institute for Exposomic Research
2020
- LinusBio incorporated
- Initial patents filed
2021
- Spinoff from Mt. Sinai completed, and worldwide license and collaboration agreement announced
- Strategic partnerships with two global biopharma companies initiated
- FDA Breakthrough
Device designation awarded to StrandDxTM – ASD to assess the likelihood of autism in children < 18 months old and to aid in diagnosis
of autism
2022
- Medical Device Regulatory Pathway for StrandDx™- ASD continued with FDA feedback and meetings
- Closed Series A financing round with Bow Capital and GPV as co-leads
future
- Establish licensed proprietary laboratory to make StrandDx™- ASD available as a laboratory developed test for pilot programs
- Determine novel molecular endpoints for collaboration partners’ drug discovery and clinical trials
